Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma--a multicenter randomized double-blind study.

TitleLiposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma--a multicenter randomized double-blind study.
Publication TypeJournal Article
Year of Publication1995
AuthorsFox LE, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Vail DM, Kisseberth W, London C, Madewell BR, Rodriguez CO
JournalCancer biotherapy
Volume10
Issue2
Pagination125-30
Date Published1995 Summer
ISSN1062-8401
KeywordsAcetylmuramyl-Alanyl-Isoglutamine, Adenocarcinoma, Animals, Antineoplastic Agents, Cat Diseases, Cats, Chemotherapy, Adjuvant, Disease-Free Survival, Double-Blind Method, Female, Follow-Up Studies, Infusions, Intravenous, Liposomes, Male, Mammary Neoplasms, Animal, Mastectomy, Radical, Neoplasm Staging, Phosphatidylethanolamines, Survival Rate
Abstract

Forty cats with previously untreated, histologically confirmed mammary gland adenocarcinoma received a radical mastectomy of the affected mammary chain(s). All cats were stratified according to clinical stage and randomized to receive either weekly intravenous liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or placebo (lipid-equivalent) for eight consecutive weeks in this double-blind study. Thirty-six of the 40 cats were available for follow-up. No significant differences in either disease-free interval or survival were found as a result of treatment. Cats with clinical stage II disease had a statistically significantly longer disease-free interval (p < 0.02), and overall survival (p < 0.005) when compared with clinical stage III cats.

Alternate JournalCancer Biother.